• Corpus ID: 21426796

Diagnosing the decline in pharmaceutical

  title={Diagnosing the decline in pharmaceutical},
  author={Scannell and Alex Blanckley and Helen Boldon},
| The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (R&D). Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80‐fold in inflation‐adjusted terms. There have been many proposed solutions to the problem of declining R&D efficiency. However, their apparent lack of impact so far… 

Figures from this paper

Regulatory Growth Theory
This research explores and quantifies the downside of technological innovations, especially the negative externality of an innovation interacting with the stock of existing innovations. Using two
Modeling ADMET.
Here, it is described in detail how ADMET models can be developed and applied using a commercially available package, ADMET Predictor™ 7.2 (AD MET Predictor v7.2.2, Simulations Plus, Inc., Lancaster, CA, USA).
Challenging the dominant logic in the healthcare industry: the case of precision medicine
  • Chie Hoon Song
  • Business, Computer Science
    Technol. Anal. Strateg. Manag.
  • 2017
The shifting nature of dominant logic in the field of PM is studied by means of qualitative analysis and several dimensions are identified to help develop a better understanding of changing business models and collaborative network structures.
Patient-Derived Xenograft vs. Organoids: A Preliminary Analysis of Cancer Research Output, Funding and Human Health Impact in 2014–2019
A preliminary analysis of the number of breast, colorectal, and lung cancer research studies using PDX or PDO published worldwide between 2014–2019 found that increases in total funding does not appear to be translating to any consequential increase in outputs, defined for this purpose as publications associated with clinical trials.
Analysis of the Parametric Correlation in Mathematical Modeling of In Vitro Glioblastoma Evolution Using Copulas
Modeling and simulation are essential tools for better understanding complex biological processes, such as cancer evolution. However, the resulting mathematical models are often highly non-linear and
The Anticancer Drug Discovery Potential of Marine Invertebrates from Russian Pacific
This review focuses on the anticancer drug discovery potential of marine invertebrates from the North-West Pacific, and suggests strategic measures to be taken on the national level in order to unleash the full-scale exploration of this potential.
Teaser Modern medicinal chemistry impacts drug discovery in many ways beyond just optimization of clinical candidates
The role of medicinal chemistry has changed over the past 10 years. Chemistry had become one step in a process; funneling the output of highthroughput screening (HTS) on to the next stage. The goal
Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution
It is proved that it is possible to obtain versatile mathematical tools which, together with a sound parametric analysis, allow to explain complex biological phenomena and the utility of this hybrid “biomimetic in vitro-in silico” platform is shown.
Improving die filling in pharmaceutical tableting by experimental and numerical means
Pharmaceutical tableting consists of three distinct stages: die filling, powder compaction, and tablet ejection. The first step is crucial with respect to the patient's safety as it defines the
A comparative effectiveness study of eSource used for data capture for a clinical research registry


The productivity crisis in pharmaceutical R&D
This study examines the decline of R&D productivity in pharmaceuticals in the past two decades and shows that this decline is associated with an increasing concentration ofR&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms.
A New Look at the Returns and Risks to Pharmaceutical R&D
This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significant
Lessons from 60 years of pharmaceutical innovation
  • B. Munos
  • Medicine
    Nature Reviews Drug Discovery
  • 2009
Analysis of the record of pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950 shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it.
Rebuilding the R&D engine in big pharma.
  • J. Garnier
  • Business, Medicine
    Harvard business review
  • 2008
A cultural revolution and a broad transformation of the organization are necessary first steps to rebuilding the R&D engine, the GlaxoSmithKline CEO says.
Unlocking the Value in Big Pharma
Size can benefit drug manufacturers, but only if they manage it. In the pharmaceuticals industry, bigger doesn't always mean better: the largest companies haven't necessarily produced the highest
How to improve R&D productivity: the pharmaceutical industry's grand challenge
A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.
Identifying R&D outliers
An analysis identifying companies — which are term ‘outliers’ — that seem to have been more successful in counteracting the overall industry trend of declining R&D productivity is presented, and an initial assessment of possible characteristics differentiating them from their less successful peers is provided.
Why has R&D productivity declined in the pharmaceutical industry?
  • R. Ruffolo
  • Business, Medicine
    Expert opinion on drug discovery
  • 2006
Some of the areas where those who manage large R&D organisations may focus to improve R&S productivity are focused on, including cost-containment and maximum use of resources.
Research Expenditures and the Discovery of New Drugs
This paper examines technical change in the ethical pharmaceutical industry. A Poisson specification is used to estimate a productivity relationship between research expenditures and drug
Challenge and Opportunity on the Critical Path to New Medical Products
i This report provides the Food and Drug Administration's (FDA's) analysis of the pipeline problem — the recent slowdown, instead of the expected acceleration, in innovative medical therapies